Umeclidinium Bromide Impurities
General Information
Umeclidinium Bromide Impurities and Umeclidinium Bromide
Daicel Pharma is a reliable supplier of high-quality Umeclidinium Bromide impurity standards, encompassing such as (1-Azabicyclo[2.2.2]octan-4-yl)(diphenyl)methanol and 4-(hydroxydiphenylmethyl)-1-(2-hydroxyethyl)quinuclidin-1-ium bromide. The presence of these impurities is crucial in conducting a comprehensive assessment of the quality, stability, and safety of active pharmaceutical ingredients. Daicel Pharma synthesizes Umeclidinium Bromide impurities to meet clients’ needs. With the ability to ship globally, customers worldwide can conveniently receive these impurities.
Umeclidinium Bromide [CAS: 869113-09-7] is a long-term maintenance bronchodilator for airflow obstruction in adults diagnosed with chronic obstructive pulmonary disease (COPD).
Umeclidinium Bromide: Use and Commercial Availability
Umeclidinium bromide belongs to the class of long-acting muscarinic acetylcholine antagonists. It prevents the tightening of large airway muscles. This medication is for the maintenance treatment of individuals diagnosed with chronic obstructive pulmonary disease (COPD). Umeclidinium Bromide is available under the brand name Incruse Ellipta, which contains the active ingredient, Umeclidinium Bromide.
Umeclidinium Bromide Structure and Mechanism of Action
The chemical name of Umeclidinium Bromide is 4-(Hydroxydiphenylmethyl)-1-[2-[(phenylmethyl)oxy]ethyl]-1-azabicyclo[2.2.2]octanium bromide. Its chemical formula is C29H34BrNO2, and its molecular weight is approximately 508.5 g/mol.
Umeclidinium blocks muscarinic receptor M3 at the smooth muscle resulting in bronchodilation.
Umeclidinium Bromide Impurities and Synthesis
Umeclidinium Bromide impurities can arise during synthesis1 due to storage or using specific raw materials and intermediates in preparation. These impurities encompass related compounds, degradation products, and process impurities. Stringent quality control measures and analytical methods are crucial to ensure the purity and safety of Umeclidinium Bromide for patient use.
Daicel provides a comprehensive Certificate of Analysis (CoA) for Umeclidinium Bromide impurity standards such as (1-Azabicyclo[2.2.2]octan-4-yl)(diphenyl)methanol and 4-(hydroxydiphenylmethyl)-1-(2-hydroxyethyl)quinuclidin-1-ium bromide. The CoA includes detailed characterization data such as 1H NMR, 13C NMR, IR, MASS, and HPLC purity2. Additionally, upon delivery, we give 13C-DEPT. Daicel possesses the technology and expertise to synthesize any unknown Umeclidinium Bromide impurity or degradation product.
References
FAQ's
References
- Laine, Dramane I.; Palovich, Michael R.; McCleland, Brent W.; Neipp, Christopher E.; Thomas, Sonia M., Muscarinic Acetylcholine Receptor Antagonists, Glaxo Group Limited, United Kingdom, EP1740177B1, August 8, 2012
- Yehia, Ali M.; Monir, Hany H., An Umeclidinium membrane sensor; Two-step optimization strategy for improved responses, Talanta, Volume: 172, Pages: 61-67, 2017
Frequently Asked Questions
How can Umeclidinium Bromide impurities be identified?
Impurities in Umeclidinium Bromide are identified through analytical techniques, such as the HPLC.
What steps are taken to minimize impurities in Umeclidinium Bromide?
It is essential to use strategies to minimize impurities in Umeclidinium Bromide. They include high-quality starting materials and operating effective purification techniques to ensure the purity of the final product.
What are the temperature conditions required to store Umeclidinium Bromide Impurities?
Umeclidinium Bromide Impurities should be stored at a controlled room temperature between 2-8°C or as indicated on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.